AstraZeneca CEO Says Post-Crestor Future On Track As Pipeline Builds
AstraZeneca's first-half results presentation highlighted its growing early pipeline, notably in oncology, but also the increasing pain of generic erosion on its Crestor sales – underlining again the importance new drugs will play in the group's turnaround strategy.
You may also be interested in...
AstraZeneca’s total focus on its core therapy areas will ensure it keeps building external collaborations and doing deals to generate new therapies while maximizing revenues, but outright sales of non-core mature medicines are likely to be fewer going forward, according to the company’s head of business development.
AstraZeneca's legal gambit results in almost two more weeks of sales for the statin even though the court ultimately agreed with FDA on labeling carve-out for orphan indication.
Sir Andrew Witty and Pascal Soriot, CEOs of GlaxoSmithKline and AstraZeneca, respectively, are to co-chair a new steering group along with George Freeman, the UK's life sciences minister. The group will address the challenges posed to the sector by the UK's decision to withdraw from the EU.